.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after an average consequence of 11 months, clients along with metastatic intestinal cysts who received biomarker-matched therapies based upon distributing lump DNA profiling revealed a more significant medical advantage than those getting unequaled treatment.